Blocking VWF platelet binding to treat TTP.

Two articles in this issue of Blood from Feys et al and Callewaert et al, respectively, have employed very similar and elegant strategies in attempts to ameliorate the symptoms of thrombotic thrombocytopenic purpura (TTP).

[1]  H. Deckmyn,et al.  Inhibition of von Willebrand factor-platelet glycoprotein Ib interaction prevents and reverses symptoms of acute acquired thrombotic thrombocytopenic purpura in baboons. , 2012, Blood.

[2]  J. Holz,et al.  Evaluation of efficacy and safety of the anti-VWF Nanobody ALX-0681 in a preclinical baboon model of acquired thrombotic thrombocytopenic purpura. , 2012, Blood.

[3]  B. Lämmle,et al.  Initial experience from a double‐blind, placebo‐controlled, clinical outcome study of ARC1779 in patients with thrombotic thrombocytopenic purpura , 2012, American journal of hematology.

[4]  D. Lane,et al.  Unraveling the scissile bond: how ADAMTS13 recognizes and cleaves von Willebrand factor. , 2011, Blood.

[5]  J. Cavenagh,et al.  A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura. , 2011, Blood.

[6]  H. Deckmyn,et al.  Thrombotic thrombocytopenic purpura directly linked with ADAMTS13 inhibition in the baboon (Papio ursinus). , 2010, Blood.

[7]  A. Chauhan,et al.  Shigatoxin triggers thrombotic thrombocytopenic purpura in genetically susceptible ADAMTS13-deficient mice. , 2005, The Journal of clinical investigation.

[8]  T. Foroud,et al.  Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura , 2001, Nature.

[9]  D. Higgs,et al.  Articles on similar topics can be found in the following Blood collections , 2002 .

[10]  D. Wagner,et al.  Blood Coagulation, Fibrinolysis and Cellular Haemostasis ADAMTS13 exerts a thrombolytic effect in microcirculation , 2022 .